Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.1 USD | +2.67% |
|
+6.43% | +11.66% |
Jul. 09 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
Jul. 03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.66% | 14.81B | |
+20.82% | 127B | |
+21.96% | 116B | |
+23.55% | 27.69B | |
-22.97% | 19.62B | |
-17.15% | 16.26B | |
-19.03% | 15.49B | |
-48.41% | 14.39B | |
+54.78% | 14.11B | |
+135.88% | 11.79B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences Insider Sold Shares Worth $376,700, According to a Recent SEC Filing